Concepedia

Author

X. Cynthia

Washington University in St. LouisORCID

Also Known As

C Ma, C. Ma, C. X. Ma, C.X. Ma, Carolyn Ma, Claire Ma, Cynthia MA, Cynthia Ma, Cynthia X Ma, Cynthia X.

640

Publications

16.7K

Citations

66

H-Index

74

Concepts

All Affiliations

Washington University in St. LouisBaylor College of MedicineDana-Farber Cancer InstituteMayo ClinicMassachusetts General Hospital
XC

About

X. Cynthia is an author at Washington University in St. Louis specializing in breast cancer, medicine, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

27

41

2.4K

2

Health Sciences

9

9

334

3

Public Health

2

2

175

4

Engineering

1

1

71

5

African American Studies

1

1

42

X. Cynthia

×

103

Publications

9.3K

Citations

47

H-Index

YearCitations

CDK4/6 inhibition triggers anti-tumour immunity

Shom Goel, Molly J. DeCristo, April C. Watt,

Nature

2017

1.4K

Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer

Ron Bose, Shyam M. Kavuri, Adam C. Searleman,

Cancer Discovery

2012

865

TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer

Lisa A. Carey, Hope S. Rugo, P. Kelly Marcom,

Journal of Clinical Oncology

2012

489

Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)

Matthew J. Ellis, Vera J. Suman, Jeremy Hoog,

Journal of Clinical Oncology

2017

403

NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer

X. Cynthia, Feng Gao, Jingqin Luo,

Clinical Cancer Research

2017

359

64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer

Helen Lee, Anthony F. Shields, Barry A. Siegel,

Clinical Cancer Research

2017

359

NCCN Guidelines Insights: Antiemesis, Version 2.2017

Michael Berger, David S. Ettinger, J N Aston,

Journal of the National Comprehensive Cancer Network

2017

240

Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor–directed therapies

Utthara Nayar, Ofir Cohen, Christian Kapstad,

Nature Genetics

2018

233

Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models

X. Cynthia, Shirong Cai, Shunqiang Li,

Journal of Clinical Investigation

2012

220

Neratinib Efficacy and Circulating Tumor DNA Detection of <i>HER2</i> Mutations in <i>HER2</i> Nonamplified Metastatic Breast Cancer

X. Cynthia, Ron Bose, Feng Gao,

Clinical Cancer Research

2017

188

Page 1